Leukemia
DCDS4501A for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (FH 2501)
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Investigator: Oliver Press, M.D.; Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia; Status: Closed; Study ID: NCT01290549
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR
Investigator: Vivian Oehler, MD; Conditions: Chronic Myeloid Leukemia (CML); Status: Recruiting; Study ID: NCT00686218
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia (CLL); Status: Recruiting; Study ID: NCT01188681
Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients in First Complete Remission
Investigator: Elihu Estey, MD; Conditions: WT1-positive Acute Myeloid Leukemia; Status: Ongoing--Not Recruiting; Study ID: NCT00725283
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Investigator: John M. Pagel, MD; Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma; Status: Recruiting; Study ID: NCT01578707
A Phase I, Open-Label, Dose-Escalation Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Investigator: Bart Scott, MD; Conditions: Myelodysplastic Syndromes (MDS);, Chronic Myelomonocytic Leukemia (CMML);, Acute Myelogenous Leukemia (AML); Status: Closed; Study ID: NCT00528983
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS 1101 (CAL 101) as Therapy for Patients With Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01539291
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Pending; Study ID: NCT01539512
A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant
Investigator: Brenda Sandmaier, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01468467
A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT01398462
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01569295
A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission
Investigator: John M. Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma; Status: Recruiting; Study ID: NCT00476047
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)
Investigator: John Pagel, MD, PhD; Conditions: Leukemia, Lymphoma; Status: Recruiting; Study ID: NCT00918723
A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age
Investigator: John Pagel, MD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT00839982
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Investigator: Roland B. Walter, MD; Conditions: Relapsed or Refractory Leukemia; Status: Closed; Study ID: NCT00920140
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia
Investigator: Pamela S. Becker, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01120457
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01165112
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML
Investigator: Merav Bar, MD; Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia; Status: Recruiting; Study ID: NCT01640301
A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01632852
A Phase 2, Randomized, Open-label study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01565668
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01729845
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01349049
A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01465386
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate
Investigator: John M. Pagel, MD; Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome; Status: Recruiting; Study ID: NCT00988715
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations
Investigator: Elihu Estey, MD; Conditions: Acute Myeloid Leukemia; Status: Closed; Study ID: NCT00989261
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Investigator: Ajay K. Gopal, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Closed; Study ID: NCT01300247
Cyclosporine Modulation of Drug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT01342887
A Phase II Study of Fludarabine (F), Rituximab (R) and Avastin (A) Followed by RA Maintenance Therapy in Patients with Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphoid Leukemia (CLL); Status: Closed; Study ID: NCT00845104
Clofarabine in Combination with Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients with AML
Investigator: Colleen Delaney, MD, MSc; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Closed; Study ID: NCT01031368
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML
Investigator: Derek L. Stirewalt, MD; Conditions: Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01607645
Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-the-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies
Investigator: Colleen Delaney, MD; Conditions: Leukemia; Status: Pending; Study ID: NCT01690520
Join Us On